(Q36892770)

16 August 2017

1 reference

title

Clinical pharmacokinetics and use of infliximab (English)

1 reference

16 August 2017

1 reference

Ulrich Klotz

1

1 reference

16 August 2017

Alexander Teml

series ordinal

2

1 reference

16 August 2017

Matthias Schwab

series ordinal

3

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Clinical Pharmacokinetics

16 August 2017

published in

1 reference

16 August 2017

volume

46

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

645-660

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200746080-00002

16 August 2017

exact match

0 references

cites work

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746080-00002

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

12 December 2020

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

12 December 2020

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

1 reference

12 December 2020

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

12 December 2020

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

12 December 2020

Genome-wide association studies for common diseases and complex traits

1 reference

12 December 2020

Infliximab use in Crohn's disease: impact on health care resources in the UK.

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

1 reference

12 December 2020

Infliximab for the treatment of ankylosing spondylitis

1 reference

12 December 2020

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

1 reference

12 December 2020

Infliximab decreases resource use among patients with Crohn's disease.

1 reference

12 December 2020

A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis

1 reference

12 December 2020

[Suspected cases of severe side effects after infliximab (Remicade) in Germany]

1 reference

12 December 2020

The fundamental basis of inflammatory bowel disease

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

1 reference

12 December 2020

Infliximab Use and Hepatosplenic T Cell Lymphoma: Questions to Be Asked and Lessons Learned

1 reference

12 December 2020

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism

1 reference

12 December 2020

Safety of infliximab and other biologic agents in the inflammatory bowel diseases

1 reference

12 December 2020

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

12 December 2020

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

12 December 2020

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

1 reference

12 December 2020

Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature.

1 reference

12 December 2020

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

12 December 2020

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

12 December 2020

Infliximab for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

12 December 2020

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Infliximab for ulcerative colitis: finally some answers

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

1 reference

12 December 2020

Anti-tumour necrosis factor-alpha therapy in heart failure: future directions

1 reference

12 December 2020

Infliximab: in ankylosing spondylitis

1 reference

12 December 2020

Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective

1 reference

12 December 2020

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

1 reference

12 December 2020

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

1 reference

12 December 2020

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

1 reference

12 December 2020

A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients

1 reference

12 December 2020

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

12 December 2020

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

12 December 2020

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

1 reference

12 December 2020

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

12 December 2020

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

12 December 2020

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Biologics in inflammatory bowel disease: how much progress have we made?

1 reference

12 December 2020

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

1 reference

12 December 2020

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

1 reference

12 December 2020

Drug interaction between infliximab and azathioprine in patients with Crohn's disease.

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

1 reference

12 December 2020

Systematic review: Infliximab therapy in ulcerative colitis.

1 reference

12 December 2020

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

12 December 2020

Toxicity of infliximab in the course of treatment of Crohn's disease

1 reference

12 December 2020

Biological therapy in the management of recent-onset Crohn's disease: why, when and how?

1 reference

12 December 2020

Spotlight on infliximab in Crohn disease and rheumatoid arthritis

1 reference

12 December 2020

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

12 December 2020

Economics of the use of biologics in the treatment of inflammatory bowel disease

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

Infliximab treatment of rheumatoid arthritis and Crohn's disease

1 reference

12 December 2020

Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus

1 reference

12 December 2020

Risks and benefits of infliximab for the treatment of Crohn's disease

1 reference

12 December 2020

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

12 December 2020

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

1 reference

12 December 2020

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

12 December 2020

The long-term efficacy and safety of new biological therapies for psoriasis

1 reference

12 December 2020

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

1 reference

12 December 2020

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis

1 reference

12 December 2020

Novel biological strategies in inflammatory bowel diseases

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

12 December 2020

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohnʼs disease: a subanalysis of the ACCENT I study

1 reference

12 December 2020

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

12 December 2020

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

12 December 2020

Optimizing anti-TNF treatment in inflammatory bowel disease

1 reference

12 December 2020

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

12 December 2020

The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohnʼs disease

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

1 reference

12 December 2020

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

12 December 2020

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

1 reference

12 December 2020

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial

1 reference

12 December 2020

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases

1 reference

12 December 2020

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

12 December 2020

Anti-TNF-alpha therapy in ankylosing spondylitis

1 reference

12 December 2020

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy

1 reference

12 December 2020

Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup

1 reference

12 December 2020

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

1 reference

12 December 2020

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

1 reference

12 December 2020

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

10.2165/00003088-200746080-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1047302694

0 references

1 reference